GLP-1 and Dental Side Effects: What "Ozempic Teeth" Claims Actually Have Behind Them

"Ozempic teeth" spread online as a catch-all term for dental problems people blamed on GLP-1 treatment, and like a lot of internet health claims, it's a mix of real mechanism, real case reports, and a fair amount of noise. Here's what actually has documented evidence behind it, and what remains speculation.

The first documented case series

In late 2023, physicians published what they described as the first case series linking semaglutide specifically to hyposalivation — clinically reduced saliva production — in three patients¹. All three were women (median age 34) who had been using semaglutide for weight loss for a mean of 11.3 weeks when symptoms appeared, with severe oral dryness, minimal frothy saliva, and objectively low salivary flow measured on a modified Schirmer test¹. After ruling out other causes, the diagnosis given was semaglutide-induced hyposalivation. All three "resumed acceptable salivary flow" after treatment adjustments — some discontinued the drug, others were managed with saliva-stimulating medication or symptomatic care¹. The authors were explicit about the limits of what three cases can prove: "Further prospective, larger studies are warranted to confirm these findings"¹ — a case series establishes that something happened and is plausible, not how common it is.

The proposed mechanism

A 2025 narrative review dug into why a GLP-1 might cause dry mouth at all, since it isn't an obvious side effect the way nausea is². The mechanism the reviewers propose involves semaglutide's long half-life and strong albumin binding, which produces sustained activation of GLP-1 receptors present in salivary gland tissue — potentially causing those receptors to become desensitized and less responsive over time through two different cell-signaling pathways². The review also notes that pharmacovigilance data (real-world adverse-event reporting) shows semaglutide associated with oral adverse effects more frequently than some other GLP-1 drugs, which is consistent with — though doesn't independently prove — the mechanism proposed².

Why dry mouth matters for your teeth specifically

Saliva isn't just comfort — it neutralizes acid, clears food debris, and delivers minerals that help remineralize tooth enamel. Chronic dry mouth (xerostomia) from any cause, whether a GLP-1, another medication, an autoimmune condition, or simple dehydration, is a well-established risk factor for increased cavities and gum irritation in general dentistry — that link is not specific to GLP-1s, it's how oral health works. A comprehensive 2026 review on oral health and incretin-based therapies frames the practical response as patient counseling and preventive oral care rather than treatment avoidance³ — meaning the evidence-based response to this risk is talking to your dentist about it, not necessarily stopping the drug.

What this doesn't establish

None of the cited sources show that GLP-1s cause tooth decay directly, that dry mouth is a common or expected side effect versus a documented-but-uncommon one, or that "Ozempic teeth" as popularly described (a broader complaint bundling dry mouth, cavities, and unrelated cosmetic concerns) is a single, well-defined clinical entity. What's genuinely established is narrower and more useful: dry mouth is a real, mechanistically plausible, case-report-documented effect in at least some patients, and dry mouth from any cause is a real dental risk factor. That's worth knowing and mentioning to your dentist — it isn't evidence that GLP-1 treatment routinely damages your teeth.

What to actually do about it

If you notice dry mouth on a GLP-1, mention it at your next dental visit and to your prescriber — both the case series and the mechanistic review point toward symptomatic management (staying hydrated, sugar-free lozenges, and in persistent cases, saliva-stimulating treatment) rather than automatic discontinuation. It's the same disclosure principle that applies to every other GLP-1 side effect: a program that asks about your full symptom picture, not just weight-loss progress, is doing the job right — see GLP-1 side effects: what the STEP and SURMOUNT trials actually reported for the broader adverse-event data, and GLP-1 drug interactions: what to tell your prescriber for what else is worth flagging at intake.

Where this fits your provider decision

We score real medical oversight — including whether a program's intake and follow-up ask about symptoms beyond the scale — as part of our Value Score methodology. Compare that alongside price on our semaglutide and tirzepatide boards, and see intake depth broken down in our provider reviews.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.